Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807810323> ?p ?o ?g. }
- W2807810323 endingPage "652" @default.
- W2807810323 startingPage "644" @default.
- W2807810323 abstract "Background Concerns about teratogenicity and maternal and offspring complications restrict the use of lithium during pregnancy for the treatment of mood disorders. We aimed to investigate the association between in-utero lithium exposure and risk of pregnancy complications, delivery outcomes, neonatal morbidity, and congenital malformations. Methods In this meta-analysis, primary data from pregnant women and their children from six international cohorts based in the community (Denmark, Sweden, and Ontario, Canada) and in clinics (the Netherlands, UK, and USA) were analysed. Pregnancies were eligible for analysis if the pregnancy resulted in a liveborn singleton between 1997 and 2015, if health-related information was available for both mother and infant, and if the mother had a mood disorder (bipolar disorder or major depressive disorder) or if she had been given lithium during pregnancy (at least two dispensations of lithium during pregnancy that were dispensed any time from 1 month before conception until the delivery, or a single lithium dispensation during pregnancy when there was at least one other lithium dispensation within 6 months before or after this date). Pregnancies during which the mother had been prescribed known teratogenic drugs were excluded. Pregnancies were grouped into a lithium-exposed group and a mood disorder reference group. The main outcome measures were pregnancy complications, delivery outcomes, neonatal readmission to hospital within 28 days of birth, and congenital malformations (major malformations and major cardiac malformations). Analyses were done at each site by use of a shared protocol. Adjusted odds ratios (aORs) and 95% CIs were calculated by use of logistic regression models, and site-specific prevalence rates and ORs were pooled by use of random-effects meta-analytical models. Findings 22 124 eligible pregnancies were identified across the six cohorts, of which 727 pregnancies were eligible for inclusion in the lithium-exposed group (557 [77%] from register-based cohorts and 170 [23%] from clinical cohorts). Lithium exposure was not associated with any of the predefined pregnancy complications or delivery outcomes. An increased risk for neonatal readmission within 28 days of birth was seen in the lithium-exposed group compared with the reference group (pooled prevalence 27·5% [95% CI 15·8–39·1] vs 14·3% [10·4–18·2]; pooled aOR 1·62, 95% CI 1·12–2·33). Lithium exposure during the first trimester was associated with an increased risk of major malformations (pooled prevalence 7·4% [95% CI 4·0–10·7] vs 4·3% [3·7–4·8]; pooled aOR 1·71, 95% CI 1·07–2·72) but for major cardiac malformations the difference was not significant (2·1% [0·5–3·7] vs 1·6% [1·0–2·1]; pooled aOR 1·54, 95% CI 0·64–3·70). Interpretation Considering both the effect sizes and the precision of the estimates in this meta-analysis, treatment decisions for pregnant women with mood disorders must weigh the potential for increased risks of lithium during pregnancy—in particular those associated with use of lithium during the first trimester—against its effectiveness at reducing relapse. Funding None. Concerns about teratogenicity and maternal and offspring complications restrict the use of lithium during pregnancy for the treatment of mood disorders. We aimed to investigate the association between in-utero lithium exposure and risk of pregnancy complications, delivery outcomes, neonatal morbidity, and congenital malformations. In this meta-analysis, primary data from pregnant women and their children from six international cohorts based in the community (Denmark, Sweden, and Ontario, Canada) and in clinics (the Netherlands, UK, and USA) were analysed. Pregnancies were eligible for analysis if the pregnancy resulted in a liveborn singleton between 1997 and 2015, if health-related information was available for both mother and infant, and if the mother had a mood disorder (bipolar disorder or major depressive disorder) or if she had been given lithium during pregnancy (at least two dispensations of lithium during pregnancy that were dispensed any time from 1 month before conception until the delivery, or a single lithium dispensation during pregnancy when there was at least one other lithium dispensation within 6 months before or after this date). Pregnancies during which the mother had been prescribed known teratogenic drugs were excluded. Pregnancies were grouped into a lithium-exposed group and a mood disorder reference group. The main outcome measures were pregnancy complications, delivery outcomes, neonatal readmission to hospital within 28 days of birth, and congenital malformations (major malformations and major cardiac malformations). Analyses were done at each site by use of a shared protocol. Adjusted odds ratios (aORs) and 95% CIs were calculated by use of logistic regression models, and site-specific prevalence rates and ORs were pooled by use of random-effects meta-analytical models. 22 124 eligible pregnancies were identified across the six cohorts, of which 727 pregnancies were eligible for inclusion in the lithium-exposed group (557 [77%] from register-based cohorts and 170 [23%] from clinical cohorts). Lithium exposure was not associated with any of the predefined pregnancy complications or delivery outcomes. An increased risk for neonatal readmission within 28 days of birth was seen in the lithium-exposed group compared with the reference group (pooled prevalence 27·5% [95% CI 15·8–39·1] vs 14·3% [10·4–18·2]; pooled aOR 1·62, 95% CI 1·12–2·33). Lithium exposure during the first trimester was associated with an increased risk of major malformations (pooled prevalence 7·4% [95% CI 4·0–10·7] vs 4·3% [3·7–4·8]; pooled aOR 1·71, 95% CI 1·07–2·72) but for major cardiac malformations the difference was not significant (2·1% [0·5–3·7] vs 1·6% [1·0–2·1]; pooled aOR 1·54, 95% CI 0·64–3·70). Considering both the effect sizes and the precision of the estimates in this meta-analysis, treatment decisions for pregnant women with mood disorders must weigh the potential for increased risks of lithium during pregnancy—in particular those associated with use of lithium during the first trimester—against its effectiveness at reducing relapse." @default.
- W2807810323 created "2018-06-21" @default.
- W2807810323 creator A5000446863 @default.
- W2807810323 creator A5003819916 @default.
- W2807810323 creator A5004875576 @default.
- W2807810323 creator A5007317249 @default.
- W2807810323 creator A5012396834 @default.
- W2807810323 creator A5023920944 @default.
- W2807810323 creator A5029298548 @default.
- W2807810323 creator A5031527833 @default.
- W2807810323 creator A5036350371 @default.
- W2807810323 creator A5042172394 @default.
- W2807810323 creator A5046450925 @default.
- W2807810323 creator A5053276850 @default.
- W2807810323 creator A5054509306 @default.
- W2807810323 creator A5068819645 @default.
- W2807810323 creator A5071233055 @default.
- W2807810323 creator A5071507483 @default.
- W2807810323 creator A5083088232 @default.
- W2807810323 creator A5088197405 @default.
- W2807810323 date "2018-08-01" @default.
- W2807810323 modified "2023-10-12" @default.
- W2807810323 title "Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies" @default.
- W2807810323 cites W1500860855 @default.
- W2807810323 cites W1925224829 @default.
- W2807810323 cites W1955095931 @default.
- W2807810323 cites W1971436035 @default.
- W2807810323 cites W1994872919 @default.
- W2807810323 cites W2015235882 @default.
- W2807810323 cites W2051653308 @default.
- W2807810323 cites W2065819590 @default.
- W2807810323 cites W2074535951 @default.
- W2807810323 cites W2074863161 @default.
- W2807810323 cites W2077261270 @default.
- W2807810323 cites W2101263979 @default.
- W2807810323 cites W2110599035 @default.
- W2807810323 cites W2112721631 @default.
- W2807810323 cites W2129387818 @default.
- W2807810323 cites W2129653870 @default.
- W2807810323 cites W2132749734 @default.
- W2807810323 cites W2133564174 @default.
- W2807810323 cites W2141745867 @default.
- W2807810323 cites W2143238437 @default.
- W2807810323 cites W2145141773 @default.
- W2807810323 cites W2149782832 @default.
- W2807810323 cites W2160231464 @default.
- W2807810323 cites W2167193785 @default.
- W2807810323 cites W2172102086 @default.
- W2807810323 cites W2185709237 @default.
- W2807810323 cites W2333051721 @default.
- W2807810323 cites W2515535496 @default.
- W2807810323 cites W2621713722 @default.
- W2807810323 cites W4253924106 @default.
- W2807810323 doi "https://doi.org/10.1016/s2215-0366(18)30180-9" @default.
- W2807810323 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6077091" @default.
- W2807810323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29929874" @default.
- W2807810323 hasPublicationYear "2018" @default.
- W2807810323 type Work @default.
- W2807810323 sameAs 2807810323 @default.
- W2807810323 citedByCount "77" @default.
- W2807810323 countsByYear W28078103232018 @default.
- W2807810323 countsByYear W28078103232019 @default.
- W2807810323 countsByYear W28078103232020 @default.
- W2807810323 countsByYear W28078103232021 @default.
- W2807810323 countsByYear W28078103232022 @default.
- W2807810323 countsByYear W28078103232023 @default.
- W2807810323 crossrefType "journal-article" @default.
- W2807810323 hasAuthorship W2807810323A5000446863 @default.
- W2807810323 hasAuthorship W2807810323A5003819916 @default.
- W2807810323 hasAuthorship W2807810323A5004875576 @default.
- W2807810323 hasAuthorship W2807810323A5007317249 @default.
- W2807810323 hasAuthorship W2807810323A5012396834 @default.
- W2807810323 hasAuthorship W2807810323A5023920944 @default.
- W2807810323 hasAuthorship W2807810323A5029298548 @default.
- W2807810323 hasAuthorship W2807810323A5031527833 @default.
- W2807810323 hasAuthorship W2807810323A5036350371 @default.
- W2807810323 hasAuthorship W2807810323A5042172394 @default.
- W2807810323 hasAuthorship W2807810323A5046450925 @default.
- W2807810323 hasAuthorship W2807810323A5053276850 @default.
- W2807810323 hasAuthorship W2807810323A5054509306 @default.
- W2807810323 hasAuthorship W2807810323A5068819645 @default.
- W2807810323 hasAuthorship W2807810323A5071233055 @default.
- W2807810323 hasAuthorship W2807810323A5071507483 @default.
- W2807810323 hasAuthorship W2807810323A5083088232 @default.
- W2807810323 hasAuthorship W2807810323A5088197405 @default.
- W2807810323 hasBestOaLocation W28078103231 @default.
- W2807810323 hasConcept C112672928 @default.
- W2807810323 hasConcept C118552586 @default.
- W2807810323 hasConcept C126322002 @default.
- W2807810323 hasConcept C131872663 @default.
- W2807810323 hasConcept C156957248 @default.
- W2807810323 hasConcept C187212893 @default.
- W2807810323 hasConcept C201903717 @default.
- W2807810323 hasConcept C2776174506 @default.
- W2807810323 hasConcept C2778541603 @default.
- W2807810323 hasConcept C2779234561 @default.
- W2807810323 hasConcept C2780733359 @default.
- W2807810323 hasConcept C54355233 @default.